Unison Pharmaceuticals Private Limited

Unison Pharmaceuticals Private Limited, established on June 1, 2001, in Ahmedabad, Gujarat, India, is a privately held pharmaceutical company specializing in the development, manufacturing, and marketing of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24232GJ2001PTC079092. As of the financial year ending March 31, 2024, Unison reported a total revenue of ₹300.59 crore, reflecting a 29.61% increase from the previous year. The company's authorized capital stands at ₹10 crore, with a paid-up capital of ₹8.81 crore. Unison employs approximately 1,434 professionals, indicating a robust workforce dedicated to its operations. The registered office is located at Unison House, Nr. Prernatirth Derasar Nr. Ratnadeep-II, Satellite, Jodhpur, Ahmedabad, Gujarat, 380015.

Unison Pharmaceuticals operates two state-of-the-art manufacturing facilities that adhere to stringent Good Manufacturing Practice (GMP) standards. These facilities are accredited by the European Union (EU), Therapeutic Goods Administration (TGA), and other regulatory agencies, ensuring compliance with international quality standards. The manufacturing units are equipped to produce a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic segments. (pharmasource.global)

The leadership team at Unison Pharmaceuticals is headed by Managing Director Bhagyesh Nitinbhai Shah, who has been at the helm since October 27, 2013. Nitin Rasiklal Shah serves as a Director, also appointed on October 27, 2013. Under their guidance, the company has experienced significant growth, with a 29.61% increase in total operating revenue for the financial year ending March 31, 2024.

Unison Pharmaceuticals has made significant strides in regulated markets, obtaining approvals from various international regulatory bodies. The company's manufacturing facilities hold certifications from the European Union (EU) and the Therapeutic Goods Administration (TGA), indicating compliance with stringent quality standards. These approvals facilitate Unison's entry into markets such as the EU and Australia, where regulatory compliance is paramount. Additionally, the company's products are registered in countries like Kenya and Uganda, expanding its reach in the African market. (pharmasource.global)

Unison Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are registered in Kenya and Uganda, enhancing its footprint in the African continent. While specific details regarding registrations in Latin America and Southeast Asia are not provided, Unison's commitment to global expansion suggests ongoing efforts to penetrate these regions. The company's adherence to international quality standards, as evidenced by its GMP certifications, positions it favorably for market access in these emerging economies. (pharmasource.global)

Unison Pharmaceuticals demonstrates a diversified geographic strategy by establishing a strong presence in both domestic and international markets. Domestically, the company has been ranked first in Gujarat state since 2006 and among the top 40 companies in India, reflecting its significant market share. Internationally, Unison has expanded its footprint in regulated markets such as the EU and Australia, as well as emerging markets in Africa. This strategic diversification mitigates concentration risk and positions the company for sustained growth across various regions.

Specific details regarding Unison Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's focus on markets such as the EU, Australia, and Africa suggests that its primary regulatory engagements may be concentrated in these regions. However, without explicit information, a comprehensive assessment of Unison's FDA status cannot be provided.

Unison Pharmaceuticals' manufacturing facilities are accredited with Good Manufacturing Practice (GMP) certifications from the European Union (EU) and the World Health Organization (WHO). These certifications attest to the company's commitment to maintaining high-quality standards in its manufacturing processes. The EU GMP certification is particularly significant, as it facilitates access to European markets, where regulatory compliance is stringent. The WHO GMP certification further underscores Unison's adherence to global quality standards, enhancing its credibility in international markets. (pharmasource.global)

Unison Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facilities are compliant with CDSCO regulations, ensuring that its products meet the required quality standards for both domestic and international markets. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to CDSCO guidelines indicates a robust regulatory framework supporting its operations.

As of March 28, 2026, there are no publicly available records indicating that Unison Pharmaceuticals has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. The absence of such records suggests that the company maintains a strong compliance track record with regulatory agencies. However, without access to specific inspection reports or regulatory communications, a detailed assessment cannot be provided.

Unison Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors in overlapping therapeutic categories are not identified, the company's diverse product portfolio and international certifications position it favorably in the market. The absence of publicly available data on market share comparisons and head-to-head analyses limits a comprehensive competitive assessment. Nonetheless, Unison's strategic focus on both domestic and international markets, along with its commitment to quality, suggests a competitive edge in the industry.

Unison Pharmaceuticals' key differentiators include its extensive experience of over four decades in the pharmaceutical industry, a diverse product portfolio spanning various therapeutic segments, and manufacturing facilities accredited with EU and WHO GMP certifications. These strengths enable the company to offer high-quality, cost-effective pharmaceutical products that meet international standards. Additionally, Unison's strategic expansion into both regulated and emerging markets demonstrates its adaptability and commitment to global healthcare solutions.

Unison Pharmaceuticals is strategically positioned as a Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO), focusing on the development, manufacturing, and marketing of finished pharmaceutical formulations. The company's mission is to be recognized as a leading global healthcare company by offering innovative, cost-effective, and high-quality pharmaceutical products. Unison aims to achieve this by establishing a strong presence in both domestic and international markets by 2030. This strategic direction underscores the company's commitment to growth, innovation, and global healthcare advancement.

Unison Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a significant increase in total operating revenue by 29.61% for the financial year ending March 31, 2024. The company maintains a consistent export volume, with a total export value of $10.6 million USD across 397 shipments from 2022 to 2026. The product portfolio is concentrated, with the top five products accounting for 100% of exports, indicating a focused approach to its offerings. The company's adherence to international quality standards, as evidenced by its GMP certifications, and its strategic expansion into both regulated and emerging markets, reflect its reliability and commitment to delivering quality pharmaceutical products.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the product is listed in the FDA's Orange Book, indicating approval for sale in the U.S. market.

• WHO-GMP Certification: Verify the WHO-GMP certificate issued by the World Health Organization, which can be obtained from the manufacturer's official website or the WHO's official site.

• EU GMP Certification: Check for the EU GMP certificate, which is typically available on the manufacturer's website or through the European Medicines Agency (EMA).

• ISO Certification: Ensure the manufacturer holds ISO certifications relevant to pharmaceutical manufacturing, such as ISO 9001:2015, which can be verified through the International Organization for Standardization's official website.

When considering Unison Pharmaceuticals as a supplier, importers should undertake the following due diligence steps:

• Verify Regulatory Approvals: Confirm